---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124542"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:20:26.272462+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress

## Summary
- Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.
- Net loss for Q3 2024 was $49.0M, compared to $20.8M in Q3 2023.
- APG777 Phase 2 Part A data expected in 2H 2025; interim Phase 1 data for APG808 in 4Q 2024.
- APG333 development candidate nominated; Phase 1 planned for late 2024 or early 2025.
- Jeff S. Hartness appointed as Chief Commercial Officer in September 2024.

## SEC filing metadata
- accession: 0000950170-24-124542
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000095017024124542/0000950170-24-124542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000095017024124542/apge-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124542
- JSON: https://secwatch.observer/filing/0000950170-24-124542.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124542.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.